Sana Shahram, J <strong>Vaccines</strong> Vaccin <strong>2013</strong>, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0163 rd International Conference on<strong>Vaccines</strong> & VaccinationJuly 29-31, <strong>2013</strong> Embassy Suites Las Vegas, NV, USAPromising horizons: Physicians as HPV vaccine advocatesSana ShahramUniversity of British Columbia, CanadaIn an effort to increase uptake and acceptance of a publically-funded school-based HPV vaccination program in BritishColumbia, general practitioners in Oncology (GPO’s) in British Columbia (BC), were surveyed to identify potentialopportunities to involve them as public advocates for the program. Family physicians are one of parents’ most trusted sourcesof information regarding their children's health. GPOs, or a general practitioner who provides oncology care in a primary caresetting, are particularly well suited to serving as HPV vaccine advocates since as general practitioners they are parents’ likelysource for information about the vaccine. Additionally, as physicians who treat cervical cancer, their intimate knowledge aboutthe morbidity and mortality associated with it, makes them particularly passionate about the vaccine, and the prevention ofthe disease. 42 GPO’s in BC completed a mailed or online survey regarding their current practices, knowledge, and resourceneeds concerning HPV, the vaccine, and the HPV immunization program, and their willingness to be contacted to participatein stated public HPV vaccine supporter activities. The survey found that 42% of surveyed GPOs were willing to act as publicsupporters of the HPV vaccine. The survey also identified education needs among GPOs concerning HPV, the vaccine, and theHPV immunization program in BC. This study found that GPOs in BC are willing to publicly support the HPV immunizationprogram and that involving physicians in the promotion of public health programs is a viable option that should be furtherexplored and evaluated.BiographySana Shahram is currently pursuing her Ph.D. in Interdisciplinary Studies at the University of British Columbia (UBC), in Kelowna, BC, Canada. Herresearch focuses on issues of maternal health among vulnerable populations. She holds a master’s in Public Health from Tufts School of Medicinein Boston, with a concentration in Health Communications as well as a B.Sc. (Cell biology/Genetics) and B.A. (English Literature) from UBC inVancouver. She also currently works as a Research Coordinator for UBC’s Department of Obstetrics and Gynaecology, based out of BC Women’sHospital in Vancouver, Canada.sanashahram@gmail.comJ <strong>Vaccines</strong> Vaccin <strong>2013</strong>ISSN: 2157-7560, JVV an open access journal<strong>Vaccines</strong>-<strong>2013</strong>July 29-31, <strong>2013</strong>Volume 4 Issue 5Page 74
Humberto Hernandez et al., J <strong>Vaccines</strong> Vaccin <strong>2013</strong>, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0163 rd International Conference on<strong>Vaccines</strong> & VaccinationJuly 29-31, <strong>2013</strong> Embassy Suites Las Vegas, NV, USAProduction and characterization of monoclonal antibodies to Ebola glycoproteinsHumberto Hernandez 1 , V. Borisevich 1 , C. Marceau 2 , A. Marzi 2 , H. Feldmann 2 and B. Rockx 11University of Texas Medical Branch, USA2National Institutes Health, MTEbolavirus hemorrhagic fever is a severe, often-fatal disease in humans and nonhuman primates, with a case fatality rate of upto 90%. There is currently no vaccine or therapeutic against Ebolavirus approved for use in humans. There are five identifiedspecies of Ebolavirus that include Bundibugyo, Ivory Coast, Reston, Sudan and Zaire and limited cross-protection is observedbetween these 5 Ebolavirus species. One of the key steps in any virus infection occurs when a virus binds to and enters a cell. TheEbolavirus glycoprotein mediates viral attachment and entry into host cells. Based on sequence homology between virus strains,we hypothesize that conserved epitopes are present on the Ebolavirus glycoprotein of all known species that can be targeted bymonoclonal antibodies. We tested this hypothesis by generating monoclonal antibody producing hybridomas from splenocytes ofBalb/c mice vaccinated against Zaire Ebolavirus glycoproteins and boosted with Sudan Ebolavirus GP. ELISA was used to identifymonoclonal antibodies that reacted with the GP of all known Ebolavirus species. In an effort to map these conserved epitopes, weperformed Western blots to determine whether these antibodies recognized conformational or linear epitopes, and used phagedisplay libraries and sequence analysis to map the epitopes onto the structure of the Ebolavirus GP. The monoclonal antibodiesproduced in this study can be used to further our understanding of mechanisms of filovirus cross-reactivity and develop broadreactivediagnostics for ebolaviruses.BiographyHumberto Hernandez completed B.S. in Biology at Lamar University. He is currently part of the Post-Baccalaureate Research Education Program(PREP) at the University of Texas Medical Branch (UTMB). Humberto Hernandez has won several awards including Burroughs Welcome FundTravel Award for the ASM National Meeting, travel scholarship, best poster, and presentation award at SACNAS National Conference, and travelaward winner for predoctoral poster presentation at the Institute for Human Infections and Immunity (IHII)/ James W. McLaughlin Colloquium atUTMB. He will start his Ph.D. at University of North Texas Health Science Center in Fort Worth, TX in August.huhernan@UTMB.EDUJ <strong>Vaccines</strong> Vaccin <strong>2013</strong>ISSN: 2157-7560, JVV an open access journal<strong>Vaccines</strong>-<strong>2013</strong>July 29-31, <strong>2013</strong>Volume 4 Issue 5Page 75
- Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
- Page 3 and 4:
Medical SciencesISSNAddiction Resea
- Page 5 and 6:
Impact Factors (IF) and Index Coper
- Page 7 and 8:
111 th OMICS Group Conference3 rd I
- Page 9 and 10:
Journal of Clinical & Cellular Immu
- Page 11 and 12:
111 th OMICS Group Conference3 rd I
- Page 13 and 14:
111 th OMICS Group Conference3 rd I
- Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
- Page 17 and 18:
Immunology Summit-2013OMICS Group i
- Page 19 and 20:
Probiotics-2013OMICS Group is organ
- Page 21 and 22:
Virology-2013OMICS Group is organiz
- Page 23 and 24: 111 th OMICS Group Conference3 rd I
- Page 25 and 26: Because of heightened awareness of
- Page 27 and 28: 111 th OMICS Group Conference3 rd I
- Page 29 and 30: 111 th OMICS Group Conference3 rd I
- Page 31 and 32: 111 th OMICS Group Conference3 rd I
- Page 33 and 34: Ara Hovanessian, J Vaccines Vaccin
- Page 35 and 36: Nikolai Petrovsky, J Vaccines Vacci
- Page 37 and 38: 111 th OMICS Group Conference3 rd I
- Page 39 and 40: Robert E. Sievers et al., J Vaccine
- Page 41 and 42: Xiao-Qing Wei, J Vaccines Vaccin 20
- Page 43 and 44: Campbell Bunce, J Vaccines Vaccin 2
- Page 45 and 46: Hong Xin, J Vaccines Vaccin 2013, 4
- Page 47 and 48: Diane Longo et al., J Vaccines Vacc
- Page 49 and 50: Track 33: Novel Approaches in Desig
- Page 51 and 52: Takashi Kei Kishimoto, J Vaccines V
- Page 53 and 54: Benjamin Petsch, J Vaccines Vaccin
- Page 55 and 56: A. Bennett Jenson et al., J Vaccine
- Page 57 and 58: Milan Raska et al., J Vaccines Vacc
- Page 59 and 60: Muhammad Ali A. Shah et al., J Vacc
- Page 61 and 62: Track 44: Vaccines against Infectio
- Page 63 and 64: Haval Shirwan, J Vaccines Vaccin 20
- Page 65 and 66: Rainer Fischer, J Vaccines Vaccin 2
- Page 67 and 68: Alwyn Rapose, J Vaccines Vaccin 201
- Page 69 and 70: Saroj Basak, J Vaccines Vaccin 2013
- Page 71 and 72: Gisela Gonzalez, J Vaccines Vaccin
- Page 73: Young Research ForumSession ChairPe
- Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
- Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
- Page 81 and 82: Kaissar Tabynov et al., J Vaccines
- Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
- Page 85 and 86: Track 5 & 95: Manufacturing, Produc
- Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
- Page 89 and 90: Obradovic Zarema et al., J Vaccines
- Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
- Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
- Page 95 and 96: 111 th OMICS Group Conference3 rd I
- Page 97 and 98: Regina Heidenreich et al., J Vaccin
- Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
- Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
- Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
- Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
- Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
- Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
- Page 111 and 112: Byung Chul Kim et al., J Vaccines V
- Page 113 and 114: STS. Chitradevi et al., J Vaccines
- Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
- Page 117 and 118: 111 th OMICS Group Conference3 rd I
- Page 119 and 120: Afshineh Latifynia et al., J Vaccin
- Page 121 and 122: Hemanta Koley et al., J Vaccines Va
- Page 123 and 124: Aleksandar Masic et al., J Vaccines
- Page 125 and 126:
Hassen Mamo, J Vaccines Vaccin 2013
- Page 127 and 128:
Oladipo Aina et al., J Vaccines Vac
- Page 129 and 130:
Aiswariya Chidambaram, J Vaccines V
- Page 131 and 132:
Birhanu Hurisa et al., J Vaccines V
- Page 133 and 134:
Ghaffarifar F et al., J Vaccines Va
- Page 135 and 136:
Mathan Periasamy et al., J Vaccines
- Page 137 and 138:
Rania Abdel Hay, J Vaccines Vaccin
- Page 139 and 140:
Samuel Teshome, J Vaccines Vaccin 2
- Page 141 and 142:
111 th OMICS Group Conference3 rd I
- Page 143 and 144:
Birhanu Hurisa et al., J Vaccines V
- Page 145 and 146:
Dhrubajyoti Nag, J Vaccines Vaccin
- Page 147 and 148:
Belachew Etana et al., J Vaccines V
- Page 149 and 150:
Fatemeh Ghaffarifar et al., J Vacci
- Page 151 and 152:
Moustafa A.F. Abbas et al., J Vacci
- Page 153 and 154:
Prerna Chaudhary, J Vaccines Vaccin
- Page 155 and 156:
Sandeepkumar R. Chauhan et al., J V
- Page 157 and 158:
Veronica Rainone et al., J Vaccines
- Page 159 and 160:
Page 159
- Page 161 and 162:
Previous111 th OMICS Group Conferen
- Page 163 and 164:
PreviousWorld Congress and Expo onB